Kolon TissueGene (950160) Q1 2026 earnings summary

Executive summary

• Focus on cell and gene therapy platform (TG-C) for osteoarthritis, with U.S. Phase 3 clinical trials completed for knee OA and Phase 2/1 approvals for hip OA and degenerative disc disease (DDD).

• Revenue primarily from B2B technology out-licensing and health/beauty distribution; U.S. market entry and global expansion planned.

• Significant R&D investment, with pipeline expansion into musculoskeletal and autoimmune diseases.

Financial highlights

• Q1 2026 revenue: $963K (USD), down from $3.6M in 2025 and $3.7M in 2024.

• Operating loss Q1 2026: $(3.7)M; net loss $(68.2)M, with negative EPS of $(4.09).

• Cash and equivalents at Q1 2026: $62.7M; total assets $337.4M; equity $82.5M.

• R&D expenses Q1 2026: $18.5M (1,923% of sales), reflecting heavy investment in clinical trials.

• High debt ratio: liabilities $254.9M, equity $82.5M; debt-to-equity ratio 233%.

Outlook and guidance

• Plans to file for FDA BLA after 2-year follow-up of Phase 3 knee OA trial.

• Pipeline expansion into hip OA, DDD, rheumatoid arthritis, and animal health.

• Commercialization strategy includes direct sales in the U.S. and licensing in other regions.